Dreamlopments Foundation attended the signing ceremony on the Ravidasvir collaboration

20 March 2024, Dr. Nicolas Durier, General Director of Dreamlopments (DLP) Foundation attended the signing ceremony of the “Collaborative & License Agreement for Ravidasvir” between Pharco Pharmaceuticals (Egypt), Drugs for Neglected Diseases Initiative (DNDi) and the Faculty of Pharmacy of Mahidol University.

Ravidasvir, manufactured by Pharco Pharmaceuticals, is a highly effective drug used to treat hepatitis C infection which is a major public health burden in Thailand. This initiative is supported by the Drugs for Neglected Diseases Initiative (DNDi) which co-signed this agreement.

Furthermore, Ravidasvir is now being used as a key medicine in the C-FREE-CSEA study by Dreamlopments Foundation.

Then Pharco Pharmaceuticals and DNDi colleagues visited the C-FREE-CSEA study Drop-in-Centers Samrong managed by our partner Raks Thai Foundation.

Signing Ceremony of the Collaborative & License Agreement for Ravidasvir

At C-FREE-CSEA study Drop-in-Centers Samrong

At C-FREE-CSEA study Drop-in-Centers Samrong